Home | Articles | Case Reports | Images | Supplements | Podcast Episodes | Translational Videos

Biologic Vs Conventional Therapies: Comparing Risk of Psoriasis-Associated Comorbidities

Psoriasis is associated with multiple comorbidities. In this retrospective cohort analysis, we compared the comorbidities in patients who received biologic treatments with those who received conventio…

Cross-Sectional Study of Psoriasis, Atopic Dermatitis, Rosacea, and Alopecia Areata Suggests Association With Cardiovascular Diseases

Background: A growing body of evidence suggests that several inflammatory skin diseases (ISDs) are associated with systemic inflammation and cardiovascular disease (CVDs). Methods: We used the TriNet…

Evaluating Sentiment, Engagement, and Perception of Biologics Among Patients
With Psoriasis and Psoriatic Arthritis on Reddit

Nicole Maynard BS^a, Danielle Yee MD^a, Camila Carranza BS^a, Manan Mehta BS^a, Rasika Reddy BA^b, Caterina Zagona-Prizio BS^c, Sabrina Khan BS^a, Samiya Khan BS^d, April W. Armstrong MD MPH^a

Background: Limited analyses of social media content among psoriasis (PsO) and psoriatic arthritis (PsA) patients exist. These patients may turn to social media to gain insight into treatments such as biologics.

Patient Preference for Calcipotriene and Betamethasone Dipropionate Cream
Versus Foam for the Topical Treatment of Psoriasis: A Pilot Study

Charles Kircik ^a, Leon H. Kircik MD^b

Background: The well-established sequential use of topical calcipotriene and topical betamethasone dipropionate in combination has been shown to provide greater benefit than either monotherapy. A newer topical fixed combination formulation of calcipotriene 0.005% and betamethasone dipropionate 0.064% in a cream base (Cal/BD cream) is effective with high patient ratings for convenience and tolerability. The current study compares patient satisfaction between Cal/BD foam and Cal/BD cream formulations.

Breaking the Frustrating Cycle of Topical Steroids in Psoriasis: A Review of a Novel Vehicle for Fixed-Dose Combination Halobetasol Propionate/Tazarotene

Leon Kircik MD^a, Neal Bhatia MD^b, Edward Lain MD^c, Abby Jacobson MS PA-C^d

Topical therapies are commonly used to treat psoriasis, either as monotherapy for milder disease or as adjuncts to systemic and biologic drugs. Topical steroids and tazarotene are both options for topical psoriasis treatment, but as monotherapies, they are associated with adverse events (AEs) that make adherence to prescribed treatment challenging.

Meeting Patient Expectations of Topical Psoriasis Treatment: Evidence Supporting the Use of Fixed-Combination Halobetasol/Tazarotene Lotion

James Del Rosso DO^a, George Han MD^b, April Armstrong MD^c, G. Michael Lewitt MD^d, Abby Jacobson PA-C^e

Discordance between patient and clinician treatment goals and expectations can present a challenge to implementation of effective therapeutic plans…

Efficacy and Safety of Water-Free Lipid Formulation System Containing Calcipotriol Against Psoriasis Vulgaris

Jan Holmback PhD^a,b, Anders Carlsson PhD^c, Puneet Rinwa PhD^b

Calcipotriol, a vitamin D analogue is widely used in the treatment of psoriasis. However, poor adherence to topical therapy has led to an ineffective use of the medication and built a barrier to the treatment’s success…

An Investigator-Initiated Trial of a Polymeric Emulsion of Halobetasol Propionate and Tazarotene in the Treatment of Palmoplantar Psoriasis

Jenna Yousif BS^a, Folawiyo Babalola BSA^b, Caroline R. Campbell MD^a, Alice B. Gottlieb MD PhD^a, Jessica Vargas ^a, Krystal Mitchell MD MBA^a

Objective: To evaluate the synergistic effect of a fixed-combination topical lotion composed of halobetasol propionate 0.01% and tazarotene 0.045% in the treatment of palmoplantar psoriasis.

Examining the Potential for Koebnerization and Disease Precipitation in Cicatricial Alopecias

Lauren Fried MD^a*, Melissa R. Laughter MD PhD^b*, Katerina Svigos MD^a, Avani M. Kolla MD^a, Daniel Gutierrez MD^a, Jerry Shapiro MD^a*, Prince Adotama MD^a**, Kristen Lo Sicco MD^a**

The treatment of primary scarring alopecias is challenging and patients may be susceptible to koebnerization. This predisposes cicatricial alopecia patients to worsening of their disease following procedural treatments or interventions.

Biological Therapy Interruption and Re-Treatment in Chronic Plaque Psoriasis

Charlie Yue Wang MBBS, Peter Foley MD FACD, Chris Baker MBBS FACD, Marius Rademaker FRCP DM

While biological treatments for chronic plaque psoriasis should be administered continuously to maximize and maintain efficacy, interruptions in therapy may be necessary for a number of reasons. We reviewed the evidence from clinical trials on efficacy, safety and immunogenicity in clinical trials for approved biologic agents for chronic plaque psoriasis. A systematic search of three major medical databases was performed and a total of 35 articles were included into the analysis, including 13 controlled trials. J Drugs Dermatol. 2021;20(10):1063-1071. doi:10.36849/JDD.5716 Read more. 

A Retrospective Review of Patients’ Response to Biologic Therapy for Psoriasis

Jerry Bagel MD MS, Brianna Butler MS PA-C, Elise Nelson LPN CCRC, Alexa Hetzel MS PA-C

Biologic treatments have taken the forefront in treating moderate-to-severe psoriasis. Although numerous randomized, controlled trials have demonstrated the efficacy of these agents, there is limited data suggesting that clinical trial outcomes are reproducible in real-world patients. J Drugs Dermatol. 20(4):442-449. doi:10.36849/JDD.2021.5823  Read more.